- 2022.09.10
We are passionate about creating transformational therapies through innovation to address unmet medical needs in oncology for patients worldwide.
Lemzoparlimab CD47
Uliledlimab CD73
TJ-CD4B Claudin 18.2 x 4-1BB
TJ-L14B PD-L1 x 4 -1BB
mRNA, Probody
AI Design, Alphabody
Lemzoparlimab CD47
Uliledlimab CD73
TJ-CD4B Claudin 18.2 x 4-1BB
TJ-L14B PD-L1 x 4 -1BB
mRNA, Probody
AI Design, Alphabody
Press Releases
2022.09.13
I-Mab has successfully completed an EoP2 meeting with the CDE of China’s NMPA, and has obtained approval to initiate a Phase 3 registrational trial evaluating lemzoparlimab in combination with AZA for the first-line treatment of patients with newly diagnosed HR-MDS.
2022.09.10
I-Mab today announces encouraging data from its Phase 2 clinical trial of lemzoparlimab in combination with azacitidine in patients with newly diagnosed HR-MDS.
2022.09.06
I-Mab today announced that the results from its Phase 2 clinical study of lemzoparlimab in combination with azacitidine in patients with HR-MDS will be featured in a proffered paper presentation at the upcoming ESMO Congress 2022.
Events
I-Mab was established in June 2016
I-Mab completed Series A financing, raising $10 million
Third Venture Biopharma and Tasgen merged to form I-Mab, raising $150 million in Series B Financing
I-Mab successfully raised $220 million in Series C Financing
I-Mab was listed on the Nasdaq Global Market as a clinical-stage biotech company
I-Mab and AbbVie enter into global strategic partnership on development and commercialization of I-Mab's novel CD47 monoclonal antibody lemzoparlimab
I-Mab entered into $418 million private placement agreement with Hillhouse Capital-led consortium
I-Mab established its global footprint with 9 locations, including new R&D site in San Diego, and new GMP facility in Hangzhou
I-Mab and Jumpcan entered into a strategic partnership for commercialization of I-Mab’s highly differentiated long-acting recombinant human growth hormone, eftansomatropin alfa in mainland China
“Clinical researchers are real life superheroes providing innovative treatments to those in need.”
“I'm inspired by my colleagues' dedication to excellence in the work that we do; their kindness and care make it easy to work together on challenging projects.”
“At I-Mab, gender inclusivity is not a tagline. The Company provides various platforms for female employees to flourish. We feel much supported in our personal and career development.”
